<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00597753</url>
  </required_header>
  <id_info>
    <org_study_id>AFX01-12</org_study_id>
    <nct_id>NCT00597753</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis</brief_title>
  <acronym>EMERALD 1</acronym>
  <official_title>AFX01-12: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated With Epoetin Alfa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affymax</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Affymax</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study was to evaluate the safety and efficacy of peginesatide in the
      maintenance treatment of anemia in participants on dialysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anemia associated with chronic kidney disease is due to several factors, primarily the
      inability of the diseased kidneys to produce adequate amounts of endogenous erythropoietin.
      Ancillary factors include the shortened lifespan of red blood cells, iron and other
      nutritional deficiencies, infection, and inflammation. The presence and severity of anemia
      are related to the duration and extent of kidney failure. Anemia is associated with increased
      mortality, increased likelihood of hospitalization, reduced cognitive function, and increased
      left ventricular hypertrophy and heart failure.

      Erythropoiesis stimulating agents (ESAs) have been established as a treatment for anemia in
      chronic renal failure subjects, and have improved the management of anemia over alternatives
      such as transfusion. Peginesatide is a parenteral formulation developed for the treatment of
      anemia in patients with chronic kidney disease. Peginesatide binds to and activates the human
      erythropoietin receptor, and stimulates erythropoiesis in human red cell precursors in a
      manner similar to other known erythropoiesis-stimulating agents.

      Eligible participants were randomized in a 2:1 ratio to peginesatide administered once every
      4 weeks or to continued treatment with epoetin alfa administered 1-3 times each week,
      respectively. Total commitment time for this study was 4 weeks of screening followed by a
      minimum of 52 weeks of study treatment.

      To evaluate the cardiovascular safety of peginesatide, a cardiovascular composite safety
      endpoint (CSE) was defined for use in prospectively planned analyses which combined
      cardiovascular safety data from the four Phase 3 peginesatide studies (NCT00598273,
      NCT00597753, NCT00598442, and NCT00597584). The CSE consisted of six events: death, stroke,
      myocardial infarction, and serious adverse events of congestive heart failure, unstable
      angina, and arrhythmia. An independent Event Review Committee (ERC) was used to provide
      blinded adjudication of potential CSE events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Hemoglobin Between Baseline and the Evaluation Period</measure>
    <time_frame>Baseline and Weeks 29-36</time_frame>
    <description>The baseline hemoglobin value is defined as the mean of five hemoglobin values: the four most recent hemoglobin values taken prior to the day of randomization and the value obtained on the day of randomization. The mean hemoglobin during the Evaluation Period for each participant is calculated as the mean of the available hemoglobin values during study Weeks 29 through 36.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who Receive Red Blood Cell (RBC) Transfusions During the Titration and Evaluation Periods</measure>
    <time_frame>Weeks 0 to 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Whose Mean Hemoglobin Level During the Evaluation Period is Within the Target Range of 10.0 - 12.0 Grams Per Deciliter (g/dL)</measure>
    <time_frame>Weeks 29 to 36</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">803</enrollment>
  <condition>Chronic Renal Failure</condition>
  <condition>Chronic Kidney Disease</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Peginesatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Epoetin alfa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginesatide</intervention_name>
    <description>Participants received peginesatide by intravenous injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa dose. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 grams per deciliter (g/dL) and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.</description>
    <arm_group_label>Peginesatide</arm_group_label>
    <other_name>Omontys</other_name>
    <other_name>Hematide</other_name>
    <other_name>AF37702 Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin Alfa</intervention_name>
    <description>Participants continued to receive commercially available epoetin alfa by intravenous injection, at the same starting dose and frequency as received during the last week of the Screening Period, with the first study dose of epoetin alfa administered after randomization at Week 0. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.</description>
    <arm_group_label>Epoetin alfa</arm_group_label>
    <other_name>Epogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Participants with chronic renal failure on hemodialysis for ≥ 3 months prior to
             randomization.

          2. On intravenous epoetin alfa maintenance therapy continuously prescribed for a minimum
             of 8 weeks prior to randomization.

          3. Four consecutive hemoglobin values with a mean ≥ 10.0 and ≤ 12.0 g/dL during the
             screening period

        Exclusion Criteria

          1. Females who are pregnant or breast-feeding.

          2. Known intolerance to any erythropoiesis stimulating agent (ESA) or pegylated molecule
             or to all parenteral iron supplementation products.

          3. Known bleeding or coagulation disorder.

          4. Known hematologic disease or cause of anemia other than renal disease

          5. Poorly controlled hypertension

          6. Evidence of active malignancy within one year prior to randomization.

          7. Temporary (untunneled) dialysis access catheter.

          8. A scheduled kidney transplant

          9. A scheduled surgery that may be expected to lead to significant blood loss.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vice President, Clinical Development</last_name>
    <role>Study Director</role>
    <affiliation>Affymax</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Paragould</city>
        <state>Arkansas</state>
        <zip>72450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Fairfield</city>
        <state>California</state>
        <zip>94533</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Granada Hills</city>
        <state>California</state>
        <zip>91344</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Lynwood</city>
        <state>California</state>
        <zip>90262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Monterey Park</city>
        <state>California</state>
        <zip>91754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facilities (2)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>San Dimas</city>
        <state>California</state>
        <zip>91773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Middlebury</city>
        <state>Connecticut</state>
        <zip>06762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Hudson</city>
        <state>Florida</state>
        <zip>34667</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Evergreen Park</city>
        <state>Illinois</state>
        <zip>60805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Columbus</city>
        <state>Mississippi</state>
        <zip>39705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <zip>07724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Yonkers</city>
        <state>New York</state>
        <zip>10710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Roseburg</city>
        <state>Oregon</state>
        <zip>97471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facilities (2)</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Sumter</city>
        <state>South Carolina</state>
        <zip>29150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Dyersburg</city>
        <state>Tennessee</state>
        <zip>38024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37923</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Grand Prairie</city>
        <state>Texas</state>
        <zip>75050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facilities (2)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77091</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Mechanicsville</city>
        <state>Virginia</state>
        <zip>23116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facilities (2)</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Appleton</city>
        <state>Wisconsin</state>
        <zip>54956</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Oshkosh</city>
        <state>Wisconsin</state>
        <zip>54904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Fishbane S, Schiller B, Locatelli F, Covic AC, Provenzano R, Wiecek A, Levin NW, Kaplan M, Macdougall IC, Francisco C, Mayo MR, Polu KR, Duliege AM, Besarab A; EMERALD Study Groups. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med. 2013 Jan 24;368(4):307-19. doi: 10.1056/NEJMoa1203165.</citation>
    <PMID>23343061</PMID>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2008</study_first_submitted>
  <study_first_submitted_qc>January 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2008</study_first_posted>
  <results_first_submitted>April 26, 2012</results_first_submitted>
  <results_first_submitted_qc>June 22, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 30, 2012</results_first_posted>
  <disposition_first_submitted>August 16, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>August 16, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 19, 2010</disposition_first_posted>
  <last_update_submitted>February 6, 2013</last_update_submitted>
  <last_update_submitted_qc>February 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anemia</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>CKD</keyword>
  <keyword>chronic renal failure</keyword>
  <keyword>CRF</keyword>
  <keyword>dialysis</keyword>
  <keyword>erythropoietin</keyword>
  <keyword>EPO</keyword>
  <keyword>erythropoiesis stimulating agent</keyword>
  <keyword>ESA</keyword>
  <keyword>Hematide™</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>hemoglobin</keyword>
  <keyword>Hb</keyword>
  <keyword>Hgb</keyword>
  <keyword>Omontys</keyword>
  <keyword>peginesatide</keyword>
  <keyword>red blood cell</keyword>
  <keyword>red blood cell production</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Peginesatide</title>
          <description>Participants received peginesatide by intravenous injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa dose. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 grams per deciliter (g/dL) and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.</description>
        </group>
        <group group_id="P2">
          <title>Epoetin Alfa</title>
          <description>Participants continued to receive commercially available epoetin alfa by intravenous injection, at the same starting dose and frequency as received during the last week of the Screening Period, with the first study dose of epoetin alfa administered after randomization at Week 0. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="532">Randomization was 2:1 peginesatide to epoetin alfa</participants>
                <participants group_id="P2" count="271"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="366"/>
                <participants group_id="P2" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued Dialysis</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Never dosed</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relocation</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Renal transplant</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site closed by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site elected to close</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Peginesatide</title>
          <description>Participants received peginesatide by intravenous injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa dose. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 grams per deciliter (g/dL) and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.</description>
        </group>
        <group group_id="B2">
          <title>Epoetin Alfa</title>
          <description>Participants continued to receive commercially available epoetin alfa by intravenous injection, at the same starting dose and frequency as received during the last week of the Screening Period, with the first study dose of epoetin alfa administered after randomization at Week 0. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="524"/>
            <count group_id="B2" value="269"/>
            <count group_id="B3" value="793"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Ten participants were excluded from the full analysis population: 8 participants in the Peginesatide group and 2 participants in the Epoetin Alfa groups. These 10 participants did not receive study medication.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="370"/>
                    <measurement group_id="B2" value="190"/>
                    <measurement group_id="B3" value="560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.3" spread="13.96"/>
                    <measurement group_id="B2" value="57.5" spread="13.68"/>
                    <measurement group_id="B3" value="57.4" spread="13.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="231"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="293"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Hemoglobin Between Baseline and the Evaluation Period</title>
        <description>The baseline hemoglobin value is defined as the mean of five hemoglobin values: the four most recent hemoglobin values taken prior to the day of randomization and the value obtained on the day of randomization. The mean hemoglobin during the Evaluation Period for each participant is calculated as the mean of the available hemoglobin values during study Weeks 29 through 36.</description>
        <time_frame>Baseline and Weeks 29-36</time_frame>
        <population>Full Analysis Population: All randomized participants who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Peginesatide</title>
            <description>Participants received peginesatide by intravenous injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa dose. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 grams per deciliter (g/dL) and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants continued to receive commercially available epoetin alfa by intravenous injection, at the same starting dose and frequency as received during the last week of the Screening Period, with the first study dose of epoetin alfa administered after randomization at Week 0. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Hemoglobin Between Baseline and the Evaluation Period</title>
          <description>The baseline hemoglobin value is defined as the mean of five hemoglobin values: the four most recent hemoglobin values taken prior to the day of randomization and the value obtained on the day of randomization. The mean hemoglobin during the Evaluation Period for each participant is calculated as the mean of the available hemoglobin values during study Weeks 29 through 36.</description>
          <population>Full Analysis Population: All randomized participants who received at least one dose of study medication</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="524"/>
                <count group_id="O2" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline [N=524, 269]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.30" spread="0.523"/>
                    <measurement group_id="O2" value="11.32" spread="0.493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evaluation Period [N=445, 248]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.06" spread="0.932"/>
                    <measurement group_id="O2" value="11.25" spread="0.846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline [N=445, 248]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.956"/>
                    <measurement group_id="O2" value="-0.09" spread="0.922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The sample size for this study was determined based on a two group evaluation of non-inferiority using the t-distribution (one-sided significance level 0.025) with a non inferiority margin of -1.0 g/dL. A sample size of approximately 750 (peginesatide group of 500 and epoetin alfa group of 250) provided at least 99% power for the evaluation of non-inferiority, assuming an expected treatment difference of 0.0 g/dL and a standard deviation of 1.5 g/dL.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority margin of -1.0 g/dL was used in the primary efficacy assessments. Non-inferiority was established if the lower limit of the two-sided 95% confidence interval for the difference between the means of the primary endpoint (peginesatide minus control ESA) was ≥ –1.0 g/dL.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.072</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants Who Receive Red Blood Cell (RBC) Transfusions During the Titration and Evaluation Periods</title>
        <time_frame>Weeks 0 to 36</time_frame>
        <population>Full Analysis Population: All randomized participants who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Peginesatide</title>
            <description>Participants received peginesatide by intravenous injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa dose. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 grams per deciliter (g/dL) and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants continued to receive commercially available epoetin alfa by intravenous injection, at the same starting dose and frequency as received during the last week of the Screening Period, with the first study dose of epoetin alfa administered after randomization at Week 0. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants Who Receive Red Blood Cell (RBC) Transfusions During the Titration and Evaluation Periods</title>
          <population>Full Analysis Population: All randomized participants who received at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="524"/>
                <count group_id="O2" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.103"/>
                    <measurement group_id="O2" value="0.086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants Whose Mean Hemoglobin Level During the Evaluation Period is Within the Target Range of 10.0 - 12.0 Grams Per Deciliter (g/dL)</title>
        <time_frame>Weeks 29 to 36</time_frame>
        <population>Full Analysis Population: All randomized participants who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Peginesatide</title>
            <description>Participants received peginesatide by intravenous injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa dose. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 grams per deciliter (g/dL) and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants continued to receive commercially available epoetin alfa by intravenous injection, at the same starting dose and frequency as received during the last week of the Screening Period, with the first study dose of epoetin alfa administered after randomization at Week 0. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants Whose Mean Hemoglobin Level During the Evaluation Period is Within the Target Range of 10.0 - 12.0 Grams Per Deciliter (g/dL)</title>
          <population>Full Analysis Population: All randomized participants who received at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="524"/>
                <count group_id="O2" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.630"/>
                    <measurement group_id="O2" value="0.717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Peginesatide</title>
          <description>Participants received peginesatide by intravenous injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa dose. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 grams per deciliter (g/dL) and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.</description>
        </group>
        <group group_id="E2">
          <title>Epoetin Alfa</title>
          <description>Participants continued to receive commercially available epoetin alfa by intravenous injection, at the same starting dose and frequency as received during the last week of the Screening Period, with the first study dose of epoetin alfa administered after randomization at Week 0. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="304" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>B-lymphocyte abnormalities</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cyanosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Electromechanical dissociation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hypertensive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Mitral valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pericarditis uraemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal arteriovenous malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Tuberous sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism secondary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism tertiary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Gastritis hypertrophic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Large intestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Oesophageal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Oesophageal dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Short-bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Catheter related complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Catheter thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hepatic congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hepatic mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Iodine allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Catheter sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Catheter bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Arteriosclerotic gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Bacterial disease carrier</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Bronchitis pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Campylobacter intestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Candida sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Central line infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Chest wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Emphysematous cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Genital abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Neurosyphilis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pleural infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pseudomonal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Psoas abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Septic embolus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Wound infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Vascular graft complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Contrast media reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Eschar</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Gastrointestinal anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Open wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Post procedural haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Postoperative fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pubic rami fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Spinal cord injury cervical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Therapeutic agent toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Anticoagulation drug level above therapeutic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>International normalised ratio decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Prothrombin time shortened</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Sputum culture positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Calciphylaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic unconsciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis pyrophosphate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Connective tissue disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Neurilemmoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Refractory anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Retroperitoneal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Anoxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Complex partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Diabetic autonomic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Myoclonic epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Reversible ischaemic neurological deficit</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Spinal cord infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Thalamus haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Homicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Schizophrenia, paranoid type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Bladder perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Nephrosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Ureteric dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Breast calcifications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Laryngeal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Restrictive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Panniculitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Steal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Arterial disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Venous stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="445" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="235" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Vascular graft complication</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="269"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="524"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="269"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first publication of the primary safety and efficacy results will include data from all appropriate study sites. Either after the first multicenter publication, or following 36 months after the completion of the study, Investigators are free to publish; such publications may not contain Sponsor Confidential Information and may be subject to Sponsor review 60 days prior to submission for publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Clinical Development</name_or_title>
      <organization>Affymax</organization>
      <phone>650-812-8700</phone>
      <email>info@affymax.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

